Skip to main content

Table 1 The characteristics and type of complications in complicated eyes treated for retinopathy of prematurity by intravitreal Bevacizumab

From: Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors

Eye number GA (weeks) BW (grams) Gender Time of first treatment (days after birth) Zone of ROP Stageof ROP Presence of NVI Complications
1 27 850 M 73 1 3 No Visually lost eye
2 27 850 M 73 1 3 No Visually lost eye
3 26 800 F 95 2 3 No Visually lost eye
4 26 800 F 95 2 3 No Visually lost eye
5 29 1600 M 66 1 3 Yes Progression to stage 4A
6 29 1600 M 66 1 3 Yes Progression to stage 4A
7 28 1000 F 59 2 3 No Progression to stage 4A and 5
8 28 1360 M 38 2 3 No Cataract
9 30 1550 F 77 2 3 No Progression to stage 4A
10 30 1550 F 77 2 3 No Progression to stage 4A
11 26 930 F 61 2 3 No Cataract
12 29 1200 F 42 1 3 No Progression to stage 4A and 5
13 29 1200 F 42 1 3 No Progression to stage 4A and 5
14 27 1000 F 57 1 3 No Progression to stage 4A
15 27 1000 F 57 1 3 No Progression to stage 4A
16 28 1300 F 45 1 3 Yes Progression to stage 4A and 5
17 28 1300 F 45 1 3 Yes Progression to stage 4A
18 25 895 M 70 1 3 Yes Vitreous hemorraghe
19 28 1300 F 74 2 3 No Progression to stage 4A
20 28 1300 F 74 2 3 No Progression to stage 4A
  1. GA gestational age, BW birth weight, ROP retinopathy of prematurity, NVI iris neovascularization, M male, F female